The 12 most recent market catalysts affecting $CDT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bearish
Impact 75
CDT Equity shares are trading lower after the company announced a 1-for-25 reverse stock split effective September 28.
A 1-for-25 reverse stock split is a significant corporate action that typically indicates a company's stock price has fallen to very low levels, potentially below exchange minimums…
Sep 25, 2026
Corporate Catalyst
Neutral
Impact 75
CDT Equity Announces 1-For-25 Reverse Stock Split, Effective September 28
This reverse stock split by CDT Equity is a significant corporate action, primarily aimed at boosting the per-share price to meet exchange listing requirements and potentially attr…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
Sarborg Shareholder CDT Equity Notes The Company's Successful Application Of Its Patented Signature Intelligence And Quantum Computing Models To Mental Health And Neuropsychiatric Drug Discovery
The filing announces that Sarborg, a private company, has successfully used its patented Signature Intelligence and quantum computing models for mental health and neuropsychiatric …
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 75
CDT Equity shares are trading lower after the company announced that, following share issuances and warrant exercises, it had 13.7 million shares outstanding, valuing the firm at about $23 million despite resolving Nasdaq deficiencies.
The primary impact here is on CDT Equity due to significant share dilution. The increase in outstanding shares from 13.7 million, coupled with a relatively low $23 million valuatio…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
CDT Equity Reports $23M Market Value And No Remaining Nasdaq Deficiencies
CDT Equity reported its market value and outstanding shares, which provides an updated snapshot of its capitalization. The most significant news, however, is the resolution of all …
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 85
CDT Equity (CDT) Shares Fall 21% After Hours: Here's What Happened
CDT Equity's stock plummeted after two 8-K filings revealed the exercise of 12.13 million pre-funded warrants, significantly increasing the outstanding share count to 13.69 million…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 75
CDT Equity Appoints James Bligh As CEO
CDT Equity Inc. announced the appointment of James Bligh, a co-founder of Conduit Pharmaceuticals Limited (now CDT), as its new CEO. This is a significant leadership change, as Mr.…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 75
CDT Equity Announced That New Solid Forms And Alternative Crystal Structures Of Its Existing Drug Compounds, Show Enhanced Physical Property Advantages, Including Improved Stability, Solubility, Manufacturability, Over Existing Forms Of These Compounds
This announcement is a significant positive catalyst for CDT Equity. Improved stability, solubility, and manufacturability of existing drug compounds can dramatically reduce develo…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
CDT Equity Announces Deal To Raise Sarborg Stake To 22.7% Via Pre-Funded Warrants For Up To 12,131,770 Shares, Subject To August 28 Shareholder Approval
This headline indicates a significant corporate action where CDT Equity is looking to increase its ownership in Sarborg to a substantial 22.7%. The use of pre-funded warrants for u…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 85
CDT Equity shares are trading lower after the company announced a 1-for-10 reverse stock split.
A reverse stock split, while increasing the per-share price, does not change the company's overall market capitalization or fundamental value. Investors often view it as a desperat…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 75
CDT Equity Approves 1-For-10 Reverse Stock Split
CDT Equity's approval of a 1-for-10 reverse stock split, effective July 17, 2026, is a significant corporate action. Reverse stock splits are often implemented by companies whose s…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 92
Conduit Pharmaceuticals Q1 EPS $(5.56) Up From $(3.67 thousand) YoY
Conduit Pharmaceuticals' Q1 earnings report reveals a dramatic increase in per-share losses, from $(3.67 thousand) to $(5.56) year-over-year. This 99.85% increase in losses is a si…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.